ENADANADH improves cognitive impairment of Alzheimer patients

ENADANADH improves cognitive impairment of Alzheimer patients

Although significant progress has been achieved in revealing the etiology of AD,
the search for efficient therapy stays the main goal. Nicotinamide adenine
dinucleotide (NADH) is biologically identified as a cofactor necessary for a
number of cellular actions, such as energy production, cell regulation and DNA
repair, enhancement of cellular immune system and repair of oxidative damage.
NADH is thought to be reduced in patients with neurodegenerative disorders and
in clinical trials NADH has been shown to improve cognitive functioning in
patients with AD, Parkinson’s disease and in chronic fatigue syndrome.
This was randomized, double blind, placebo-controlled study with aim to
establish weather NADH would improve cognitive functioning in patients with AD.
48 patients were randomized in the study, 24 were allocated to placebo and 24 to
NADH treatment. Primary outcome measure was the difference in Mattis
Dementia Rating Scale total score between baseline and after six months of
treatment. The rest of cognitive tests included Hopkins Verbal Learning Test,
Fuld Object Memory Test, Matching to Sample Test, Verbal Fluency Test, Clinical
Dementia Rating Scale and Mini Mental Status Scale Exam.
NADH subjects improved significantly compared to placebo group in verbal
fluency test. Placebo group experienced decrease of verbal fluency for 0.5 fewer
words per minute and NADH group showed improvement of verbal fluency for
3.5 more words per minute (p=0.056). Six months after baseline a mean
increase in MDRS Total score for NADH group was 2.8 (+/- 1.76) and for placebo
group a mean decrease in MDRS Total score -4.9 (+/- 3.13) points (p=0.022).
The results from this trial consistently demonstrate benefit of stabilized oral
NADH on cognitive functioning in AD patients.

nadhwiki has written 69 articles

Leave a Reply